These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 3407549)
21. PAF induces rat plasma extravasation and releases eicosanoids during anaphylaxis. Jancar S; Sirois MG; Carrier J; Braquet P; Sirois P Inflammation; 1991 Oct; 15(5):347-54. PubMed ID: 1757122 [TBL] [Abstract][Full Text] [Related]
22. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. Okamoto H; Iwahisa Y; Terasawa M Agents Actions; 1992 Mar; 35(3-4):149-58. PubMed ID: 1388318 [TBL] [Abstract][Full Text] [Related]
23. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Piper PJ; Stewart AG Br J Pharmacol; 1986 Jul; 88(3):595-605. PubMed ID: 3091131 [TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats. Ohmori K; Ishii H; Kubota T; Shuto K; Nakamizo N Arch Int Pharmacodyn Ther; 1985 May; 275(1):139-50. PubMed ID: 2862849 [TBL] [Abstract][Full Text] [Related]
25. A comparison of the anti-anaphylactic activities of salbutamol and disodium cromoglycate in the rat, the rat mast cell and in human lung tissue. Butchers PR; Fullarton JR; Skidmore IF; Thompson LE; Vardey CJ; Wheeldon A Br J Pharmacol; 1979 Sep; 67(1):23-32. PubMed ID: 115530 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological analysis of the vascular permeability response in the anaphylactic phase of allergic inflammation in rats. Ohuchi K; Hirasawa N; Watanabe M; Tsurufuji S Eur J Pharmacol; 1985 Nov; 117(3):337-45. PubMed ID: 4076349 [TBL] [Abstract][Full Text] [Related]
27. The role of platelet-activating factor and peptidoleukotrienes in the vascular changes of rat passive anaphylaxis. Fernández-Gallardo S; Gijón MA; García C; Furio V; Liu FT; Sánchez Crespo M Br J Pharmacol; 1992 Jan; 105(1):119-25. PubMed ID: 1596674 [TBL] [Abstract][Full Text] [Related]
28. A method for evaluating anti-allergic drugs by simultaneously induced passive cutaneous anaphylaxis and mediator cutaneous reactions. Koda A; Miura T; Inagaki N; Sakamoto O; Arimura A; Nagai H; Mori H Int Arch Allergy Appl Immunol; 1990; 92(3):209-16. PubMed ID: 1703513 [TBL] [Abstract][Full Text] [Related]
29. A pharmacological study of SRS-A on the bovine cutaneous vasculature. Burka JF; Eyre P Can J Physiol Pharmacol; 1977 Aug; 55(4):904-8. PubMed ID: 902163 [TBL] [Abstract][Full Text] [Related]
30. In vivo pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Nakagawa N; Obata T; Kobayashi T; Okada Y; Nambu F; Terawaki T; Aishita H Jpn J Pharmacol; 1992 Nov; 60(3):217-25. PubMed ID: 1337128 [TBL] [Abstract][Full Text] [Related]
31. Immediate inhibition by oral l-ephedrine of passive cutaneous anaphylaxis of rats: indirect inhibition of anaphylactic chemical mediator release from the mast cell. Shibata H; Minami E; Hirata R; Mizutani N; Nabe T; Kohno S Inflamm Res; 2000 Oct; 49(10):553-9. PubMed ID: 11089909 [TBL] [Abstract][Full Text] [Related]
32. Immediate inhibitory effect of methylprednisolone suleptanate (U-67590A) on antigen-induced cutaneous and airway anaphylactic responses in guinea-pigs. Hashimoto M; Shinozaki Y; Katori M Br J Pharmacol; 1993 Mar; 108(3):604-12. PubMed ID: 7682130 [TBL] [Abstract][Full Text] [Related]
33. Role of hyaluronidase in immediate hypersensitivity reaction. Sakamoto K; Nagai H; Koda A Immunopharmacology; 1980 Apr; 2(2):139-46. PubMed ID: 6777331 [TBL] [Abstract][Full Text] [Related]
34. Differential effect of a PAF antagonist CV-3988 on active and passive anaphylactic shock in various mouse strains. Arimura A; Harada M Lipids; 1991 Dec; 26(12):1386-90. PubMed ID: 1819738 [TBL] [Abstract][Full Text] [Related]
35. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988. Issekutz AC; Szpejda M Lab Invest; 1986 Mar; 54(3):275-81. PubMed ID: 3951199 [TBL] [Abstract][Full Text] [Related]
36. Antiallergic activity of 6-(2-cyclohexylethyl)-[1,3,4]thiadiazolo- [3,2-a]-1,2,3-triazolo-[4,5-d]pyrimidin-9(3H)-one (DS-4574) in rats. Aibara S; Mori M; Tsubokawa M; Iwamoto T; Tsukada W Int Arch Allergy Immunol; 1992; 98(2):146-52. PubMed ID: 1379506 [TBL] [Abstract][Full Text] [Related]
37. Suppression by adrenoceptor beta-agonists of vascular permeability increase and edema formation induced by arachidonate metabolites, platelet-activating factor, and tumor-promoting phorbol ester TPA. Ohuchi K; Watanabe M; Hirasawa N; Yoshizaki S; Mue S; Tsurufuji S Immunopharmacology; 1990; 20(2):81-8. PubMed ID: 1979974 [TBL] [Abstract][Full Text] [Related]
38. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. Handley DA; Lee ML; Saunders RN Thromb Haemost; 1985 Dec; 54(4):756-9. PubMed ID: 4089809 [TBL] [Abstract][Full Text] [Related]
39. [Effect of mao-bushi-saishin-to (MBST), a formula of Chinese medicines, on 48 hr homologous passive cutaneous anaphylaxis in rats]. Shibata H; Kohno S; Ohata K Arerugi; 1995 Sep; 44(9):1167-75. PubMed ID: 8534213 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the activity of a platelet activating factor antagonist, CV-3988. Hayashi M; Kimura J; Oh-Ishi S; Tsushima S; Nomura H Jpn J Pharmacol; 1987 Jun; 44(2):127-34. PubMed ID: 2888915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]